

December 1, 2015



# Actinium Announces Strong Presence at 57th American Society of Hematology Annual Meeting December 4-8, 2015

**Activity Highlights Include: Poster Presentation of Actimab-A Clinical Trial Data, Educational Outreach for Iomab-B Phase 3 Trial, Clinical and Scientific Advisory Board Meetings, Business and Clinical Development Activities**

NEW YORK, NY -- (Marketwired) -- 12/01/15 --

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company announced today its active schedule at the upcoming 57<sup>th</sup> American Society of Hematology (ASH) Annual Meeting being held December 4-8, 2015 in Orlando, FL.

***Key Highlights of Actinium's Activities at ASH 2015 include:***

- *Poster presentation of data from the Phase 1 trial for Actimab-A, a CD33 targeting radioimmunotherapy with Orphan Drug Designation.*
- *A special educational event in preparation for the planned Iomab-B Phase 3 clinical trial. The seminar entitled "Iomab-B in Refractory AML: Can Older Patients with Active Disease be Transplanted?" will be held Monday, December 7, 2015. The expected audience includes physicians from a wide array of disciplines, investors, analysts and the media.*
- *Special meetings of the Clinical and Scientific Advisory Boards to discuss the Actimab-A Phase 1/2 Trial and planned Iomab-B Phase 3 Trial respectively, with participation from Key Opinion Leaders from major medical institutions such as Columbia University Medical Center, MD Anderson Cancer Center, Memorial Sloan Kettering, Swedish Medical Center, Baylor University and others.*
- *Business and Clinical development activities involving Iomab-B and Actimab-A.*

"This year's American Society of Hematology Annual Meeting represents a point of transformation for Actinium. Our activities, including physician engagement and business development, are focused on our transition to a later stage company as we move towards a pivotal, Phase 3 trial for Iomab-B and Phase 2 trial for Actimab-A. We are pleased with Actimab-A's strong competitive position in the renewed effort by several larger companies to develop a CD33 targeting therapy for AML and are excited to have the update of its clinical trial highlighted in a poster presentation," said Sandesh Seth, M.S., MBA, Executive

Chairman of Actinium Pharmaceuticals.

### ***About Actimab-A***

Actimab-A, Actinium's most advanced alpha particle immunotherapy program is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. Actimab-A is being developed as a first line therapy and has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile.

Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. Both the alpha particle technology and Lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.

### ***About Iomab-B***

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

### ***About Actinium Pharmaceuticals***

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

### ***Forward-Looking Statement for Actinium Pharmaceuticals, Inc.***

This news release contains "forward-looking statements" as defined in the Private Securities

Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Steve O'Loughlin  
Senior Director, Finance and Corporate Development  
Actinium Pharmaceuticals, Inc.  
[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

Source: Actinium Pharmaceuticals